Pruritus occurs in up to 70% of patients with primary biliary cholangitis (PBC), can be severe, and lead to increased morbidity-including worsening fatigue and quality of sleep. Standard of care treatment has relied on a variety of medications with limited effectiveness and tolerability adding to the patient disease burden. In this 1-hour video-based activity with animation, Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

This content is also availble as a podcast: You may listen here.

Please visit our related course, Interprofessional Care of Patients with Pruritus Associated with Primary Biliary Cholangitis, by clicking here.

Presenting Faculty

• 

  Alan Bonder, MD

  Medical Director of Liver Transplant
  Beth Israel Deaconess Medical Center
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts

• 

  Kris Kowdley, MD

  Director, Liver Institute Northwest
  Medical Director and Senior Scientific Advisor, Velocity Clinical Research
  Professor, Elson S. Floyd College of Medicine
  Washington State University
  Seattle, Washington